Cargando…
Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials
COVID-19 pandemic demands a swift response to find therapeutic tools that effectively reduce morbidity and mortality. Despite initial fears, evidence from retrospective observational studies supports the inhibition of the renin-angiotensin system as an emerging pathway to delay or moderate angiotens...
Autores principales: | Rothlin, Rodolfo Pedro, Duarte, Mariano, Pelorosso, Facundo Germán, Nicolosi, Liliana, Salgado, M. Victoria, Vetulli, Héctor Miguel, Spitzer, Eduardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039444/ https://www.ncbi.nlm.nih.gov/pubmed/33854432 http://dx.doi.org/10.3389/fphar.2021.603736 |
Ejemplares similares
-
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19
por: Rothlin, Rodolfo Pedro, et al.
Publicado: (2023) -
Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial
por: Duarte, Mariano, et al.
Publicado: (2021) -
The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition
por: Atlas, Steven A.
Publicado: (2007) -
COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments
por: Zolk, Oliver, et al.
Publicado: (2020) -
Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)